
Reset all filters
01 1Asmanex
02 4Dulera
03 11Nasonex
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 218
2019 Revenue in Millions : 293
Growth (%) : -26
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 206
2020 Revenue in Millions : 218
Growth (%) : -6
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 63
2020 Revenue in Millions : 83
Growth (%) : -24
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 190
2020 Revenue in Millions : 222
Growth (%) : -14
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 238
2021 Revenue in Millions : 206
Growth (%) : 16
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 180
2021 Revenue in Millions : 190
Growth (%) : -5
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 194
2022 Revenue in Millions : 180
Growth (%) : 8
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 253
2022 Revenue in Millions : 238
Growth (%) : 6
Main Therapeutic Indication : Pulmonary/Respiratory Diseases
Currency : USD
2024 Revenue in Millions : 276
2023 Revenue in Millions : 266
Growth (%) : 4
Mometasone Furoate/Formoterol Fumarate Dihydrate
Main Therapeutic Indication : Pulmonary/Respiratory Diseases
Currency : USD
2024 Revenue in Millions : 203
2023 Revenue in Millions : 194
Growth (%) : 5